| 2025-11-13 |
详情>>
股本变动：
变动后总股本11535.23万股
|
| 2025-11-13 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.88美元,归母净利润-1.04亿美元,同比去年增长22.50%
|
| 2025-10-20 |
详情>>
内部人交易：
Adawi Kamal股份增加75000.00股
|
| 2025-08-12 |
详情>>
业绩披露：
2025年中报每股收益-0.61美元,归母净利润-7169.1万美元,同比去年增长17.05%
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益-0.32美元,归母净利润-3762.1万美元,同比去年增长21.63%
|
| 2025-04-17 |
股东大会：
将于2025-05-29召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors, as nominated by the Company’s Board of Directors (the “Board of Directors”), to hold office until the 2028 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025;
3.To conduct a non-binding advisory vote to approve the compensation of our named executive officers;
4.To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of our named executive officers;
5.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 250,000,000 to 350,000,000;
6.To approve the amendment and restatement of the Company’s 2022 Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder;
7.To approve the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals;
|
| 2025-03-05 |
详情>>
业绩披露：
2024年年报每股收益-1.64美元,归母净利润-1.86亿美元,同比去年增长-15.74%
|
| 2024-11-18 |
复牌提示：
2024-11-18 09:35:13 停牌，复牌日期 2024-11-18 09:40:13
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.19美元,归母净利润-1.34亿美元,同比去年增长-14.81%
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-0.79美元,归母净利润-8643.1万美元,同比去年增长-20.65%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.47美元,归母净利润-4800.4万美元,同比去年增长-154.25%
|
| 2024-05-09 |
财报披露：
美东时间 2024-05-09 盘后发布财报
|
| 2024-04-26 |
股东大会：
将于2024-06-07召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors, as nominated by the Company’s Board of Directors (the “Board of Directors”), to hold office until the 2027 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024;
3.To conduct a non-binding advisory vote to approve the compensation of our named executive officers;
4.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to include an officer exculpation provision that limits the liability of certain of our officers as permitted under current Delaware law;
5.To approve the amendment and restatement of the Company’s 2022 Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder;
6.To approve the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals;
7.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2024-02-26 |
详情>>
业绩披露：
2023年年报每股收益-1.64美元,归母净利润-1.61亿美元,同比去年增长42.88%
|
| 2023-11-08 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.19美元,归母净利润-1.17亿美元,同比去年增长48.17%
|
| 2023-08-08 |
详情>>
业绩披露：
2023年中报每股收益-0.73美元,归母净利润-7163.6万美元,同比去年增长49.48%
|
| 2023-04-21 |
股东大会：
将于2023-06-06召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors, as nominated by the Company’s Board of Directors (the “Board of Directors”), to hold office until the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023;
3.To conduct a non-binding advisory vote to approve the compensation of our named executive officers;
4.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2022-04-25 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors, as nominated by the Company’s Board of Directors, to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022;
3.To conduct a non-binding advisory vote to approve the compensation of our named executive officers;
4.To approve the Fate Therapeutics, Inc. 2022 Stock Option and Incentive Plan;
5.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-21 |
股东大会：
将于2021-06-02召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors, as nominated by the Company’s Board of Directors, to hold office until the 2024 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021;
3.To conduct a non-binding advisory vote to approve the compensation of our named executive officers;
4.To amend and restate our Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 150,000,000 to 250,000,000;
5.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2020-03-20 |
股东大会：
将于2020-05-01召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors, as nominated by the Company’s Board of Directors, to hold office until the 2023 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020;
3.To conduct a non-binding advisory vote to approve the compensation of our named executive officers;
4.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2019-03-22 |
股东大会：
将于2019-05-03召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors, as nominated by the Company’s Board of Directors, to hold office until the 2022 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019;
3.To conduct a non-binding advisory vote to approve the compensation of our named executive officers;
4.To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of our named executive officers;
5.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2018-03-16 |
股东大会：
将于2018-05-02召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors, as nominated by the Company’s Board of Directors, to hold office until the 2021 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018;
3.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2017-03-22 |
股东大会：
将于2017-05-02召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors, as nominated by the Company’s Board of Directors, to hold office until the 2020 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2017;
3.To approve, under applicable NASDAQ listing rules, the issuance of 14,097,745 shares of the Company’s common stock upon the conversion of 2,819,549 outstanding shares of the Company’s Class A Convertible Preferred Stock;
4.To approve an amendment and restatement of the Company’s 2013 Stock Option and Incentive Plan and to approve the material terms for payment of performance-based compensation;
5.To transact such other business as may properly come before the meeting or any adjournment or postponement.
|
| 2016-03-30 |
股东大会：
将于2016-05-11召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors, as nominated by the Board of Directors, to hold office until the 2019 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2016;
3.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|